OBJECTIVE: To determine whether antipyretic treatment for influenza infection influences the risk of mortality in animal models and humans. DESIGN: A systematic search of Medline, Embase and the Cochrane Register of Controlled Trials was undertaken to identify randomized placebo-controlled trials of antipyretic use in influenza infection in animal models or humans that reported mortality. A quantitative meta-analysis of the risk of death using Peto's one step odds ratio with calculation of the pooled risk of death and standard evaluation of heterogeneity was undertaken. SETTING: Not applicable. PARTICIPANTS: Not applicable. MAIN OUTCOME MEASURES: Risk of mortality associated with antipyretic use in influenza infection. RESULTS: Eight studies from three publications met the inclusion criteria. No human studies were identified. The risk of mortality was increased by antipyretic use in influenza-infected animals with a fixed effects pooled odds ratio of 1.34 (95% CI 1.04-1.73). An increased risk was observed with aspirin, paracetamol and diclofenac. CONCLUSION: In animal models, treatment with antipyretics for influenza infection increases the risk of mortality. There are no randomized placebo-controlled trials of antipyretic use in influenza infection in humans that reported data on mortality and a paucity of clinical data by which to assess their efficacy. We suggest that randomized placebo-controlled trials of antipyretic use in human influenza infection are urgently required, and that these are sufficiently powered to investigate a potential effect on mortality.
OBJECTIVE: To determine whether antipyretic treatment for influenza infection influences the risk of mortality in animal models and humans. DESIGN: A systematic search of Medline, Embase and the Cochrane Register of Controlled Trials was undertaken to identify randomized placebo-controlled trials of antipyretic use in influenza infection in animal models or humans that reported mortality. A quantitative meta-analysis of the risk of death using Peto's one step odds ratio with calculation of the pooled risk of death and standard evaluation of heterogeneity was undertaken. SETTING: Not applicable. PARTICIPANTS: Not applicable. MAIN OUTCOME MEASURES: Risk of mortality associated with antipyretic use in influenza infection. RESULTS: Eight studies from three publications met the inclusion criteria. No human studies were identified. The risk of mortality was increased by antipyretic use in influenza-infected animals with a fixed effects pooled odds ratio of 1.34 (95% CI 1.04-1.73). An increased risk was observed with aspirin, paracetamol and diclofenac. CONCLUSION: In animal models, treatment with antipyretics for influenza infection increases the risk of mortality. There are no randomized placebo-controlled trials of antipyretic use in influenza infection in humans that reported data on mortality and a paucity of clinical data by which to assess their efficacy. We suggest that randomized placebo-controlled trials of antipyretic use in humaninfluenza infection are urgently required, and that these are sufficiently powered to investigate a potential effect on mortality.
Authors: Carl I Schulman; Nicholas Namias; James Doherty; Ronald J Manning; Pamela Li; Pam Li; Ahmed Elhaddad; Ahmed Alhaddad; David Lasko; Jose Amortegui; Christopher J Dy; Lucie Dlugasch; Gio Baracco; Stephen M Cohn Journal: Surg Infect (Larchmt) Date: 2005 Impact factor: 2.150
Authors: Paul Jeffrey Young; Manoj Saxena; Richard Beasley; Rinaldo Bellomo; Michael Bailey; David Pilcher; Simon Finfer; David Harrison; John Myburgh; Kathryn Rowan Journal: Intensive Care Med Date: 2012-01-31 Impact factor: 17.440